The E-screen assay: a comparison of different MCF7 cell stocks

Area of Science:

• Endocrinology
• Cell Biology
• Cancer Research

Background:

• MCF7 human breast cancer cells are a standard model for studying estrogen's effects on cell growth and protein synthesis.
• The proliferative response to estrogen is a key indicator of estrogenic activity, forming the basis of the E-screen assay.

Purpose of the Study:

• To characterize and compare the E-screen assay performance of four distinct MCF7 cell stocks (BUS, ATCC, BB, and BB104).
• To identify the MCF7 cell stock exhibiting the most reliable and pronounced proliferative response to estrogen for E-screen testing.

Main Methods:

• Assaying four MCF7 cell stocks (BUS, ATCC, BB, BB104) for their biological behavior and proliferative response to estradiol-17 beta.
• Utilizing the E-screen assay, which measures MCF7 cell proliferation in response to estrogenic compounds.
• Analyzing cell cycle phase distribution (G0/G1 arrest) and receptor levels (estrogen and progesterone receptors) in response to estrogen deprivation.

Main Results:

• MCF7 BUS cells exhibited distinct behavior in the absence of estrogen, including G0/G1 arrest and altered receptor expression.
• MCF7 BUS cells demonstrated the highest proliferative response to estradiol-17 beta, with cell yields increasing up to sixfold compared to untreated cells over 144 hours.
• The proliferative differences in MCF7 BUS cells were primarily attributed to estrogen deprivation-induced G0/G1 arrest.

Conclusions:

• MCF7 BUS cells are superior for the E-screen test due to their marked proliferative response to estrogen.
• Cell stocks like MCF7 BUS, showing a strong estrogen-dependent proliferative pattern, are recommended for the E-screen assay and other studies demonstrating estrogen's proliferative effects.